ReviewFrontiers in public health2026
Advances in cardiovascular risk assessment indicators in obstructive sleep apnea.
Review in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obstructive sleep apnea (OSA) is a highly prevalent sleep-related breathing disorder that is closely associated with cardiovascular morbidity and mortality. Although the apnea-hypopnea index (AHI) remains the conventional metric for diagnosing and grading OSA severity, it inadequately reflects the heterogeneous pathophysiological burden of the disease and has limited predictive value for cardiovascular outcomes. This review summarizes recent advances in cardiovascular risk assessment indicators in OSA, with a focus on mechanisms of OSA-related cardiovascular injury, limitations of traditional metrics, emerging physiological indices, circulating biomarkers, phenotype-based stratification, and risk evaluation in patients with specific cardiovascular comorbidities. Intermittent hypoxia, sleep fragmentation, and intrathoracic pressure swings jointly contribute to sympathetic activation, oxidative stress, systemic inflammation, endothelial dysfunction, hypercoagulability, metabolic dysregulation, and cardiac remodeling. Novel physiological indicators, including hypoxic burden, heart rate response, pulse wave amplitude drop index, and respiratory effort-related metrics, may better quantify OSA-related cardiovascular stress than AHI alone. In parallel, biomarkers reflecting inflammation, endothelial dysfunction, coagulation activation, myocardial injury, and microRNA-mediated regulation show potential for identifying high-risk subgroups. Phenotype-based approaches, such as classifications integrating symptoms, hypoxic patterns, and cardiovascular risk, provide a promising framework for precision management. Future research should standardize these novel indicators, validate their associations with hard cardiovascular outcomes, and develop multimodal prediction models to guide individualized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.